AGIOS PHARMACEUTICALS, INC.

Agios is a commercial-stage biopharmaceutical company focused on discovering and developing therapies for rare hematologic conditions and genetic metabolic disorders. The company's lead commercial product is mitapivat, an oral small-molecule pyruvate kinase activator marketed under the brand names Pyrukynd and Aqvesme for indications including pyruvate kinase deficiency and alpha- or beta-thalassemia. In addition to commercializing mitapivat, Agios advances a clinical development pipeline featuring investigational candidates such as tebapivat for lower-risk myelodysplastic syndromes and sickle cell disease, AG-181 for phenylketonuria, and AG-236 for polycythemia vera. The company serves adult and pediatric patient populations diagnosed with rare hematological and metabolic diseases.

The company maintains commercial infrastructure to distribute its therapies directly in the United States and utilizes third-party distribution partners to provide access across the European Economic Area, Switzerland, the United Kingdom, and the Gulf Cooperation Council region. The excerpt does not provide information regarding the company's specific headquarters location.

Summary of the business section of Agios Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 539 full-time employees and 1 part-time employee.”